Lung cancer (LC) is the leading cause of cancer mortality. PATP was provided in experimental trials to decrease the venous

 

Abstract

Lung cancer (LC) is the leading cause of cancer mortality. PATP was provided in experimental trials to decrease the venous thromboembolism (VTE), with ultimate aim to improve overall survival (OS). We undertook an updated systematic review and meta-analysis of randomized controlled trials (RCTs) to determine the impact of PATP with LMWHs on OS and VTE in patients with LC. 5443 patients with LC from nine RCTs were included. The pooled hazard ratio (HR) for OS was 1.02 (95% CI 0.83 to 1.26; P = 0.83) and for progression or metastasis-free survival was 1.03 (95% CI 0.86 to 1.24; P = 0.74). The pooled risk ratio (RR) for VTE was 0.54 (95% CI 0.43 to 0.69; P < 0.00001)< 0.00001).

PMID: 32189065 [PubMed - as supplied by publisher]

21 March 2020

12:45

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:45

In reply to this message

pubmed: ctoall&ca or conall

Exercise Interventions in Cardio-oncology Populations: A Scoping Review of the Literature.

Related Articles

Exercise Interventions in Cardio-oncology Populations: A Scoping Review of the Literature.

J Cardiovasc Nurs. 2020 Mar 19;:

Authors: Wang HL, Cousin L, Fradley MG, Donovan KA, Smith B, Szalacha L, Lavoie Smith EM, Buck HG